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Abstract
Background: The most widely utilized approaches for quantifying DNA methylation involve the treatment of
genomic DNA with sodium bisulfite; however, this method cannot distinguish between 5-methylcytosine (5mC)
and 5-hydroxymethylcytosine (5hmC). Previous studies have shown that 5hmC is enriched in the brain, although
little is known about its genomic distribution and how it differs between anatomical regions and individuals. In this
study, we combine oxidative bisulfite (oxBS) treatment with the Illumina Infinium 450K BeadArray to quantify
genome-wide patterns of 5hmC in two distinct anatomical regions of the brain from multiple individuals.
Results: We identify 37,145 and 65,563 sites passing our threshold for detectable 5hmC in the prefrontal cortex and
cerebellum respectively, with 23,445 loci common across both brain regions. Distinct patterns of 5hmC are
identified in each brain region, with notable differences in the genomic location of the most hydroxymethylated
loci between these brain regions. Tissue-specific patterns of 5hmC are subsequently confirmed in an independent
set of prefrontal cortex and cerebellum samples.
Conclusions: This study represents the first systematic analysis of 5hmC in the human brain, identifying
tissue-specific hydroxymethylated positions and genomic regions characterized by inter-individual variation in
DNA hydroxymethylation. This study demonstrates the utility of combining oxBS-treatment with the Illumina
450k methylation array to systematically quantify 5hmC across the genome and the potential utility of this
approach for epigenomic studies of brain disorders.
Keywords: Epigenetics, DNA methylation, Brain, 5-methylcytosine, 5mC, 5-hydroxymethylcytosine, 5hmC,
EWAS, Illumina Infinium 450K Beadarray, Cerebellum
Background
Epigenetic modifications to DNA play a critical role in
establishing and maintaining cellular phenotype [1].
Recent studies highlight widespread changes in DNA
methylation occurring during neurodevelopment, with
tissue-specific methylomic variation present between
discrete regions of the human brain [2, 3]. Epigenetic
processes control key neurobiological and cognitive pro-
cesses in the brain, and their importance is highlighted
by evidence implicating methylomic variation in a num-
ber of neuropsychiatric and neurodegenerative diseases,
including multiple sclerosis, autism, Alzheimer’s disease,
and schizophrenia [4–7].
Although 5-methylcytosine (5mC) is the best under-
stood and most studied epigenetic modification modu-
lating transcriptional plasticity in the mammalian
genome, three additional DNA modifications (5-hydro-
xymethylcytosine (5hmC), 5-formylcytosine (5fC), and
5-carboxylcytosine (5caC)) have been recently described.
These modifications are thought to represent intermedi-
ates in the demethylation of 5mC to un-modified cytosine
[8] although recent data suggest there are specific func-
tional roles for 5hmC. For example, 5hmC is specifically
recognized by key binding-proteins [9], and can be main-
tained through cell division [10]. The exact genomic dis-
tribution of 5hmC is still debated; some studies have
reported 5hmC in gene promoters and gene bodies
[11, 12], while others have shown a depletion of
5hmC in CpG islands and an enrichment outside of
CG-rich regions [13, 14]. It has been shown that
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5hmC occurs at relatively high levels in the cerebel-
lum and other regions of the brain [15, 16], where it
is particularly enriched in the vicinity of genes with
synapse-related functions [17]. Of note, recent studies
have reported global alterations in 5hmC in Alzheimer’s
disease [18, 19], supporting a role in health and disease.
Until recently it has not been possible to sensitively
quantify 5hmC at base-pair resolution in the genome
across large numbers of samples. Furthermore, many of
the existing methods routinely used to interrogate DNA
methylation (that is, those based on sodium bisulfite
(BS) conversion and methylation-sensitive restriction en-
zyme cleavage) are unable to discriminate between 5mC
and 5hmC [20]. The recent development of oxidative
bisulfite (oxBS) treatment [13, 21], however, which in-
volves the oxidation of 5hmC to 5fC before BS conversion,
allows both a direct measurement of absolute 5mC and a
proxy measure of 5hmC. Two recent papers demonstrated
that oxBS conversion can be integrated with the Illumina
450K HumanMethylation (450K) array to facilitate the
systematic quantification of both 5mC and 5hmC across
the genome [22, 23]. In this study we used a com-
mercially available oxBS treatment kit (TrueMethyl-CEGX,
Cambridge, UK) in conjunction with the Illumina 450K
array to compare the distribution of 5hmC across two
regions of the human brain (prefrontal cortex and
cerebellum) dissected from eight donors. We subse-
quently confirmed our findings in an independent set
of matched prefrontal cortex and cerebellum samples
dissected from an additional 18 individuals.
Results and discussion
Identifying differences in hydroxymethylated sites
between cortex and cerebellum
The aim of the study was to compare 5hmC in matched
postmortem prefrontal cortex and cerebellum samples
from multiple donors using a commercially available oxBS
conversion kit in combination with the Illumina 450K
Human Methylation array. Briefly, the level of 5hmC at
specific sites is quantified by subtracting oxBS-generated
450K array profiles from those generated following a BS-
conversion performed in parallel. Each sample in this study
was also profiled following a standard BS-conversion
protocol using the Zymo EZ DNA methylation kit. Fol-
lowing normalization, the distribution of beta values
was highly consistent across both BS methods (CEGX
vs. Zymo) (Additional file 1: Figure S1A), with a highly
significant correlation observed in both the prefrontal
cortex (Additional file 1: Figure S1B; R2 = 0.99, P <2.2E-16)
and cerebellum samples (Additional file 1: Figure S1C;
R2 = 0.99, P <2.2E-16). These data indicate that the CEGX
BS conversion protocol yields data that are directly com-
parable to data generated using standard BS conversion
kits widely employed prior to 450K array processing.
We were interested in establishing the location of sites
characterized by ‘detectable’ 5hmC and, building on our
previous data demonstrating region-specific patterns of
5mC in the human brain [2], the extent to which levels
of 5hmC differed between the prefrontal cortex and
cerebellum. 5hmC levels were calculated by subtracting
the oxBS beta-value from the BS beta value at each
probe on the 450K array (ΔβBS-oxBS) (see Methods). As
expected, the distribution of ΔβBS-oxBS values was
positively-skewed (Fig. 1a), although a small proportion
of probes in each sample were characterized by a nega-
tive ΔβBS-oxBS value, likely resulting from technical vari-
ance inherent in the Illumina array protocol. We
therefore set a stringent threshold for calling 5hmC
based on the 95th percentile of negative ΔβBS-oxBS values
across all profiled samples, to ensure we only analyzed
probes characterized by ‘detectable’ levels of 5hmC. In this
dataset, therefore, only sites with an average ΔβBS-oxBS
level in either tissue >0.09158275 were classified as having
‘detectable’ levels of 5hmC. Using this threshold, we iden-
tified a total of 79,263 loci characterized by ‘detectable’
5hmC in one or both brain regions.
Of note, there was a striking difference in the preva-
lence of 5hmC-positive sites between the prefrontal
cortex and cerebellum (Fig. 1a); we identified 37,145
(13,700 unique) and 65,563 (42,118 unique) probes with
an average 5hmC level above threshold in the prefrontal
cortex and cerebellum, respectively, with 23,445 probes
characterized by ‘detectable’ 5hmC in both regions of
the brain (Additional file 2: Table S1, Additional file 2:
Table S2, and Fig. 1b). Of the 37,145 sites with ‘detect-
able’ 5hmC in the prefrontal cortex we observed a small
but significant correlation with 5hmC level at the same
sites in the cerebellum (Fig. 1c; adjusted R2 = 0.097,
P <2.2E-16). Similarly for the 65,563 sites with ‘de-
tectable’ 5hmC in the cerebellum we observed a signifi-
cant correlation with 5hmC in the prefrontal cortex
(Fig. 1d; adjusted R2 = 0.132, P <2.2E-16). As a resource to
other researchers interested in the distribution of 5hmC
in the brain, average ΔβBS-oxBS levels for each of the
79,263 probes on the 450K array characterized by ‘detect-
able’ 5hmC in one or both brain regions can be explored
in the Hydroxymethylation Annotation in Brain Integra-
tive Tool (HABIT) at our laboratory website (http://
epigenetics.iop.kcl.ac.uk/HMC/). The tool also integrates
annotated UCSC tracks to enable visualization of average
5hmC levels in both brain regions.
The distribution of 5hmC differs depending on genic
location and CG density
Given that the abundance of 5mC is known to vary
across the genome, we were interested in whether there
is an enrichment of 5hmC in certain annotated regions
of the genome. Although the Illumina 450K array does
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not enable an assessment of all potentially hydroxy-
methylated probes in the human genome, it is the most
widely-used tool in epigenetic epidemiology and covers
99 % of RefSeq genes, with an average of 17 CpG sites
per gene region distributed across the promoter,
5'UTR, first exon, gene body, and 3'UTR. We found
that ‘detectable’ 5hmC is highly depleted in CpG
islands in both brain regions (prefrontal cortex: OR = 0.18,
P <2.53E-294; cerebellum: OR = 0.23, P <2.53E-294).
In contrast, 5hmC is enriched in CpG island shores
(prefrontal cortex: OR = 1.55, P = 2.53E-294; cerebellum:
OR = 1.30, P = 1.80E-159), CpG island shelves (prefrontal
A B
C D
Fig. 1 Quantifying 5hmC in two regions of the human brain. a ΔβBS-oxBS was calculated for each sample and a detection threshold based on the
lowest fifth percentile in the negative values (0.09158275) used to call ‘detectable’ 5hmC (black vertical line). b We identified 37,145 and 65,563
probes with a mean 5hmC level above threshold in the prefrontal cortex and cerebellum, respectively. c The degree of hydroxymethylation at
sites with ‘detectable’ 5hmC in prefrontal cortex (N = 37,145) is correlated with levels at the same sites in the cerebellum (adjusted R2 = 0.097,
P <2.2E-16). The red horizontal line indicates our threshold for ‘detectable’ 5hmC. d The degree of hydroxymethylation at sites with ‘detectable’
5hmC in cerebellum (N = 65,563) is correlated with levels at the same sites in the prefrontal cortex (adjusted R2 = 0.132, P <2.2E-16)
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cortex: OR = 1.78, P = 3.93E-262; cerebellum: OR = 1.86, P
<2.53E-294), and locations outside of CG-rich regions
(prefrontal cortex: OR = 1.62, P <2.53E-294; cerebellum:
OR = 1.68, P <2.53E-294) (Table 1, Fig. 2a). This is consist-
ent with previous studies demonstrating a depletion of
5hmC in CpG islands and an enrichment outside of
CG-rich regions [13, 14]. Furthermore, ‘detectable’ 5hmC
was significantly enriched in both brain regions in the
gene body (prefrontal cortex: OR = 1.90, P <2.53E-294;
cerebellum: OR = 2.48, P <2.53E-294), (Table 1, Fig. 2b, c),
and also downstream of annotated transcripts (prefrontal
cortex: OR = 1.30, P = 1.95E-12; cerebellum: OR = 1.35,
P = 2.04E-25). In contrast, in both brain regions, 5hmC
was depleted at intergenic sites (prefrontal cortex: OR =
0.82, P = 8.46E-34; cerebellum: OR = 0.79, P = 5.13E-75)
and the proximal promoter (prefrontal cortex: OR = 0.54,
P <2.53E-294; cerebellum: OR = 0.40, P <2.53E-294). This
is consistent with previous studies showing a decrease in
brain 5hmC in intergenic regions [24] and an enrichment
of 5hmC in gene bodies [22]. Interestingly, 5hmC was
modestly enriched in distal promoter sites in the pre-
frontal cortex (OR = 1.19, P = 5.16E-12), but not in the
cerebellum (OR = 0.97, P = 0.166). These data concur with
previous studies using oxBS in conjunction with the 450K
array in smaller numbers of samples. Stewart et al.
demonstrated a significant enrichment of probes with de-
tectable 5hmC in gene bodies when investigating one un-
matched cerebellum and frontal cortex sample [22], while
Field et al. showed that loci with detectable 5hmC are
enriched in the gene body (exonic and intronic) and
regions downstream of the gene in a single cerebel-
lum sample [23].
5hmC is enriched in certain functional elements and
depleted in others
We used functional genomic annotation data from
ENCODE [25, 26] to examine the distribution of 5hmC
across regulatory regions of the genome in the brain.
‘Detectable’ 5hmC was found to be significantly depleted
at transcription factor binding sites (TFBS) (prefrontal
cortex: OR = 0.67, P = 8.40E-291; cerebellum: OR = 0.44,
P <2.53E-294) and at DNAse I hypersensitivity sites
(prefrontal cortex: OR = 0.88, P <7.49E-14; cerebellum:
OR = 0.68, P = 5.80E-174) (Table 1).
We also examined alternative transcription events
(Table 1; Fig. 2d) and found that 5hmC is significantly
depleted in both brain regions at alternative first exons
(AFE) (prefrontal cortex: OR = 0.72, P = 5.07E-76; cere-
bellum: OR = 0.56, P <2.53E-294) and constitutive exons
(CNE) (prefrontal cortex: OR = 0.71, P = 1.99E-38; cere-
bellum: OR = 0.80, P = 3.28E-28). In contrast, 5hmC is
significantly enriched in alternative last exons (ALE)
(prefrontal cortex: OR = 1.49, P = 1.55E-35; cerebellum:
OR = 1.59, P = 5.61E-81), cassette exons (CE) (prefrontal
cortex: OR = 1.53, P = 2.14E-128; cerebellum: OR = 1.57,
P = 1.17E-239), and mutually exclusive exons (MXE)
(prefrontal cortex: OR = 1.44, P = 8.63E-41; cerebellum:
OR = 1.39, P = 6.38E-52). This concurs with previous
studies demonstrating elevated levels of 5hmC in CE in
the human brain [17]. Furthermore, there is evidence of
cerebellum-specific enrichment of 5hmC at alternative 3’
splice site (A3SS) (OR = 1.14, P = 2.63E-03), alternative
5’ splice site (A5SS) (OR = 1.15, P = 1.11E-03), and exon
isoforms (EI) (OR = 1.78, P = 1.39E-03), with no equivalent
enrichment in matched prefrontal cortex samples. Finally,
there is depletion of 5hmC at intron retention (IR) events
in the prefrontal cortex (OR = 0.91, P = 8.9E-04), but not
the cerebellum (OR = 1.02, P = 0.472).
Using a logistic regression method to identify bio-
logical pathways enriched for loci annotated to sites with
‘detectable’ 5hmC, stringently controlling for the num-
ber probes annotated to each gene, we found consider-
able overlap in 5hmC-enriched pathways between the
prefrontal cortex (Additional file 2: Table S3) and cere-
bellum (Additional file 2: Table S4), with the most
significantly enriched pathway in both brain regions
being nervous system development (prefrontal cortex:
P = 1.5E-11; cerebellum: P = 4.1E-11).
Levels of 5hmC at specific sites differ between prefrontal
cortex and cerebellum
After describing the genomic distribution of ‘detectable’
5hmC, we were interested in estimating absolute levels
of 5hmC at specific sites, and the extent to which these
differ between brain regions and individuals. The canon-
ical patterns of 5hmC and 5mC levels across the gene
are shown in Fig. 3 for the 79,263 loci with detectable
levels of 5hmC. 5mC levels across the gene are similar
to those reported previously [2, 23], with a decrease in
levels at the TSS, before a gradual increase through the
gene body, and an eventual decrement downstream of
the gene body. Interestingly although 5mC levels are
similar at the TSS in both the prefrontal cortex and cere-
bellum, levels of 5mC were slightly elevated in the cere-
bellum at other regions along the gene, and more
notably so at the 3’ end of the transcript. In contrast,
5hmC is characterized by a different genic pattern, with
levels being consistently higher in the cerebellum than
the prefrontal cortex across the entire gene, in addition
to immediate upstream/downstream regions.
Additional file 2: Table S5 and Additional file 2: Table
S6 list the 1,000 450K array sites with the highest
estimated levels of 5hmC in the prefrontal cortex and
cerebellum, respectively. Of the sites showing highest
5hmC in the prefrontal cortex (Additional file 2:
Table S5), 349 did not exceed our detection threshold
in the cerebellum. Similarly, of the sites showing highest
5hmC in the cerebellum (Additional file 2: Table S6), 651
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Table 1 Specific genomic features are characterized by hydroxymethylation in brain
Probes passing QC on array (%) Prefrontal cortex Cerebellum
Detectable 5hmC sites (%) Enrichment (95 % CI) P value Detectable 5hmC sites (%) Enrichment (95 % CI) P value
All probes (N = 374,094) 37,145 - - 65,563 - -
CpG island feature
Island 120,922 (32.3 %) 2,868 (7.7 %) 0.18 (0.17–0.18) <2.53E-294 6,524 (10.0 %) 0.23 (0.23–0.24) <2.53E-294
Shore 87,312 (23.3 %) 11,934 (32.1 %) 1.55 (1.52–1.59) 2.53E-294 18,544 (28.3 %) 1.30 (1.27–1.32) 1.80E-159
Shelf 32,912 (8.8 %) 5,434 (14.6 %) 1.78 (1.72–1.83) 3.93E-262 9,958 (15.2 %) 1.86 (1.81–1.90) <2.53E-294
Outside 124,010 (33.1 %) 16,565 (44.6 %) 1.62 (1.59–1.66) <2.53E-294 29,831 (45.5 %) 1.68 (1.66–1.71) <2.53E-294
Unannotated 8,938 (2.4 %) 344 (0.9 %) 0.38 (0.34–0.43) 2.99E-91 706 (1.1 %) 0.44 (0.41–0.48) 9.15E-118
Gene feature
Intergenic 52,325 (14 %) 4,367 (11.8 %) 0.82 (0.79–0.85) 8.46E-34 7,461 (11.4 %) 0.79 (0.77–0.81) 5.13E-75
Distal promoter 16,990 (4.5 %) 1,986 (5.3 %) 1.19 (1.13–1.25) 5.16E-12 2,897 (4.4 %) 0.97 (0.93–1.01) 0.166
Proximal promoter 148,029 (39.6 %) 9,693 (26.1 %) 0.54 (0.53–0.55) <2.53E-294 13,544 (20.7 %) 0.40 (0.39–0.41) <2.53E-294
Gene body 140,919 (37.7 %) 19,870 (53.5 %) 1.90 (1.86–1.94) <2.53E-294 39,335 (60.0 %) 2.48 (2.44–2.52) <2.53E-294
Downstream 6,893 (1.8 %) 885 (2.4 %) 1.30 (1.21–1.40) 1.95E-12 1,620 (2.5 %) 1.35 (1.28–1.43) 2.04E-25
Unannotated 8,938 (2.4 %) 344 (0.9 %) 0.38 (0.34–0.43) 2.99E-91 706 (1.1 %) 0.44 (0.41–0.48) 9.15E-118
Transcription factor binding site 184,178 (49.2 %) 14,623 (39.4 %) 0.67 (0.66–0.68) 8.40E-291 19,499 (29.7 %) 0.44 (0.43–0.44) <2.53E-294
Dnase 1 hypersensitivity site 49,903 (13.3 %) 4,449 (12.0 %) 0.88 (0.86–0.91) 7.49E-14 6,227 (9.5 %) 0.68 (0.66–0.70) 5.80E-174
Alternative transcription events (N = 138,640 probes) 14,429 - - 25,582 - -
A3SS 3,347 (2.4 %) 330 (2.3 %) 0.95 (0.84–1.06) 0.361 700 (2.7 %) 1.14 (1.05–1.24) 2.63E-03
A5SS 3,364 (2.4 %) 357 (2.5 %) 1.02 (0.91–1.14) 0.712 710 (2.8 %) 1.15 (1.06–1.25) 1.11E-03
AFE 57,956 (41.8 %) 4,897 (33.9 %) 0.72 (0.69–0.74) 5.07E-76 7,332 (28.7 %) 0.56 (0.54–0.58) <2.53E-294
ALE 9,026 (6.5 %) 1,353 (9.4 %) 1.49 (1.40–1.58) 1.55E-35 2,554 (10.0 %) 1.59 (1.52–1.67) 5.61E-81
CE 60,203 (43.4 %) 7,783 (53.9 %) 1.53 (1.47–1.58) 2.14E-128 13,980 (54.6 %) 1.57 (1.53–1.61) 1.17E-239
CNE 20,661 (14.9 %) 1,592 (11.0 %) 0.71 (0.67–0.75) 1.99E-38 3,149 (12.3 %) 0.80 (0.77–0.83) 3.28E-28
EI 137 (0.1 %) 19 (0.1 %) 1.33 (0.78–2.16) 0.270 45 (0.2 %) 1.78 (1.24–2.51) 1.39E-03
II 27,746 (20 %) 3,080 (21.3 %) 1.08 (1.04–1.13) 1.60E-04 4,974 (19.4 %) 0.96 (0.93–1.00) 0.036
IR 16,175 (11.7 %) 1,550 (10.7 %) 0.91 (0.86–0.96) 8.90E-04 3,025 (11.8 %) 1.02 (0.97–1.06) 0.472
MXE 13,054 (9.4 %) 1,880 (13 %) 1.44 (1.37–1.52) 8.63E-41 3,221 (12.6 %) 1.39 (1.33–1.44) 6.38E-52
The level of enrichment was determined by Fisher’s exact test. QC, quality control; 5hmC, 5-hydroxymethylcytosine; CI, confidence interval; A3SS, alternative 3’ splice site; A5SS, alternative 5’ splice site; AFE, alternative
first exon; ALE, alternative last exon; CE, cassette exon; CNE, constitutive exon; EI, exon isoforms; II, intron isoforms; IR, intron retention; MXE, mutually exclusive exon
Lunnon
et
al.G
enom
e
Biology
 (2016) 17:27 
Page
5
of
14
did not exceed our detection threshold in the prefrontal
cortex. These data suggest that although there is some
similarity between brain regions, levels of 5hmC at indi-
vidual sites are often tissue-specific.
In order to confirm our findings, we subsequently ex-
amined 5hmC levels at the top 1,000 sites in additional
matched prefrontal cortex and cerebellum samples
dissected from 18 independent donors (Additional file 2:
Tables S5; Additional file 2: Table S6). Estimates of
5hmC at these sites was highly concordant across
datasets (median difference between discovery and
replication datasets = 4.73 (prefrontal cortex) and 4.62
(cerebellum)). There is a highly significant correlation
in estimated 5hmC levels between the discovery and
validation datasets at these sites in both the prefrontal
cortex (R = 0.52, P = 8.96E-36) and cerebellum (R = 0.71,
P = 7.42E-54) (Fig. 4).
Additional file 2: Table S7 lists the top 1,000 sites
characterized by the largest average differences in 5hmC
between the prefrontal cortex and cerebellum, which we
define as tissue-specific hydroxymethylated positions
(TS-HMPs). Each of these 1,000 probes is characterized
by at least 28 % hydroxymethylation difference between
the brain regions. For the majority (96.5 %) of these
probes, the difference was driven by increased 5hmC
in the cerebellum compared to the prefrontal cortex
(Additional file 1: Figure S2), although 35 of the
1,000 sites (3.5 %) did show elevated 5hmC in the
prefrontal cortex compared to the cerebellum. A total
of 997 out of the 1,000 loci showed a significant dif-
ference in 5hmC between the prefrontal cortex and
cerebellum in our validation dataset (Additional file 2:
Table S7), and there was a highly significant correlation in
prefrontal cortex versus cerebellum differences at these
A B
C D
Fig. 2 Hydroxymethylation is enriched in specific genomic features in brain. a Hydroxymethylated loci are significantly under-enriched in CpG
islands, shores, and shelves and (b, c) significantly enriched in the gene body. d Across both brain regions sites with ‘detectable’ 5hmC are
enriched in alternative last exons, cassette exons, and mutually exclusive exons, and under-enriched in alternative first exons and constitutive
exons. The level of enrichment was determined by Fisher’s exact test. QC: quality control; CGI: CpG island; SHO: CpG island shore; SHE: CpG island
shelf; nonCGI, NC: outside CpG islands; UA: unannotated; A3SS: 3’ splice site; A5SS: alternative 5’ splice site; AFE: alternative first exon; ALE: alternative last
exon; CE: cassette exon; CNE: constitutive exon; EI: exon isoforms; II: intron isoforms; IR: intron retention; MXE: mutually exclusive exon
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loci between the two independent datasets (Fig. 4c;
R = 0.49, P = 6.32E-33). Pathway analysis of these top
1,000 TS-HMPs showed an enrichment for various
neurobiological processes that distinguish the cortex
and cerebellum (Additional file 2: Table S8), for example
acetylcholine binding (P = 1.51E-04), dopaminergic neuron
differentiation (P = 1.03E-03), and cerebellar purkinje cell
layer morphogenesis (P = 1.83E-03).
Although there is an overall depletion of ‘detectable’
5hmC in CpG islands (Table 1) when compared to the
genic distribution of all probes on the 450K array, it is
notable that sites with the highest levels of 5hmC in both
the prefrontal cortex and cerebellum are enriched in CpG
islands (OR = 1.25, P = 0.022 and OR = 3.46, P = 7.01E-55,
respectively) when compared to the distribution of the
79,263 sites with ‘detectable’ 5hmC (Table 2; Additional
file 1: Figure S3A). Furthermore, we found a significant
enrichment of TS-HMRs in CpG islands (OR = 4.23,
P = 6.37E-79) (Table 3; Additional file 1: Figure S3A)
when compared to the 79,263 sites with ‘detectable’
5hmC. Conversely, TS-HMRs are depleted in both
CpG island shores (OR = 0.66, P = 6.2E-08) and CpG
island shelves (OR = 0.59, P = 2.64E-07). Interestingly
we have previously shown that tissue-specific differen-
tially methylated regions in the genome (TS-DMRs)
are enriched in CpG island shores and shelves [2], in-
dicating a clear distinction between the location of
tissue-specific DNA methylation and hydroxymethyla-
tion. The most hydroxymethylated sites in the pre-
frontal cortex showed similar patterns with respect to
an enrichment at TFBS (prefrontal cortex: OR = 2.53,
P = 2.57E-47; cerebellum: OR = 1.31, P = 4.97E-05) and
DHS (prefrontal cortex: OR = 1.54, P = 3.95E-06; cerebel-
lum: OR = 1.45, P = 8.42E-05), but some tissue differences
in their presence at alternative events (Additional file 1:
Figure S3C), and within gene features (Additional file 1:
Figure S3B). For example, the most hydroxymethylated
sites are over-represented in the proximal promoter in the
prefrontal cortex (OR = 2.11, P = 3.10E-27), but not the
cerebellum, and there is an under-representation of the
top hydroxymethylated sites at gene bodies in the
prefrontal cortex (OR = 0.64, P = 5.30E-12), but an
over-representation in the cerebellum (OR = 1.45, P =
2.60E-08). The previous study investigating 5hmC in a
single cerebellum sample also demonstrated that the
highest levels of 5hmC are found in the gene body,
within introns [23].
Some sites are characterized by considerable inter-
individual variation in 5hmC
Given the hypothesized role of 5hmC in health and
disease, we were interested in identifying regions of the
genome characterized by inter-individual variation in
5hmC within both the prefrontal cortex (Additional
file 2: Table S9) and cerebellum (Additional file 2:
Table S10). The 1,000 top-ranked variable 5hmC sites
were enriched in CpG islands both in the prefrontal
cortex: (OR = 1.72, P = 4.03E-09) and the cerebellum
(OR = 3.92, P = 2.41E-69) (Table 4; Additional file 1:
Figure S3A). Furthermore, in both tissues, highly-
variable 5hmC sites were under-represented in inter-
genic regions (Additional file 1: Figure S3B) (prefrontal
cortex: OR = 0.84, P = 0.032; cerebellum: OR = 0.63, P =
3.86E-05) and in the proximal promoter (prefrontal cor-
tex: OR = 0.76, P = 1.10E-03; cerebellum: OR = 0.47, P =
1.03E-16). However, there were some differences between
the genic location of the most variable sites between the
prefrontal cortex and the cerebellum; the most variable
sites in the prefrontal cortex were under-represented in
CpG island shelves (OR = 0.69, P = 1.82E-07), while the
most variable sites in the cerebellum were under-
represented in CpG island shores (OR = 0.52, P = 9.25E-
17). Furthermore, in the gene body there was a significant
over-representation of the most variable sites in the cere-
bellum (OR = 1.28, P = 1.78E-04), but not in the prefrontal
cortex (OR = 1.00, P = 1.000). Interestingly over-/under-
representation of sites at alternative events (Additional
file 1: Figure S3C) was only seen for the most vari-
able probes in the cerebellum and not in the pre-
frontal cortex, indicating that 5hmC may play a role
in regulating gene expression through splicing in a
tissue-specific manner. Despite observing genic differ-
ences in the most variable sites between individuals
in the prefrontal cortex and cerebellum, there was a
significant correlation in the inter-individual differences
Fig. 3 Gene-level analysis of canonical 5hmC. Levels of 5hmC are
consistently higher in the cerebellum than in the prefrontal cortex
along the length of the gene. Key: average 5hmC level in prefrontal
cortex (red), average 5hmC level in cerebellum (green), average 5mC
level in prefrontal cortex (blue), average 5mC level in
cerebellum (pink)
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between regions, with the 1,000 most variable sites in the
prefrontal cortex showing a similar degree of variability in
the cerebellum (Additional file 1: Figure S4A; R = 0.30,
P = 6.14E-17), and similarly the most variable sites in
the cerebellum showing a similar degree of variability
in the prefrontal cortex (Additional file 1: Figure S4B;
R = 0.24, P = 5.4E-12).
A small proportion of DMPs identified by epigenome-wide
association studies (EWAS) using standard BS approaches
may actually reflect differences in 5hmC
Standard BS-treatment has been used in conjunction
with the Illumina 450K methylation array in a growing
number of EWAS analyses to identify differences in
DNA methylation associated with exposure and disease.
Given that this approach actually provides a cumulative
measure of both 5mC and 5hmC, it is plausible that
variation in 5hmC could confound findings that have
largely been attributed to variation in DNA methylation.
When we identified regions with the greatest difference
in BS-generated data between the prefrontal cortex and
cerebellum (Additional file 2: Table S11), these changes
significantly correlated with differences in oxBS-generated
data (R = 0.537, P = 6.85E-37) (Additional file 1: Figure S5;
Additional file 2: Table S11). However, differences at some
loci appeared to be driven by 5hmC, rather than 5mC
variation, with eight of the top 1,000 BS tissue differences
being driven more by a 5hmC difference than a 5mC
difference. Looking across a canonical gene, we actually
see no difference in DNA modification levels between the
Fig. 4 5hmC estimates generated using this approach were validated in an independent set of matched prefrontal cortex and cerebellum
samples. Estimates of 5hmC at the 1,000 loci showing the highest levels of 5hmC in the discovery cohort were highly consistent and significantly
correlated across datasets in both (a) the prefrontal cortex (R = 0.52, P = 8.96E-36) and (b) the cerebellum (R = 0.71, P = 7.42E-54). The red line
denotes our threshold for robust 5hmC detection. (c) 5hmC differences between prefrontal cortex and cerebellum at the 1,000 top-ranked
TS-HMPs identified in the discovery cohort were significantly correlated with differences identified at the same sites in the validation cohort
(R = 0.49, P = 6.32E-33)
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prefrontal cortex and the cerebellum when using
standard BS-treated DNA (Fig. 5); however, we do see
a considerable difference in true DNA methylation
levels as determined using oxBS-treated DNA, with
higher levels at the 3’ end of the gene in the pre-
frontal cortex than the cerebellum. We therefore rec-
ommend running BS and oxBS 450K arrays in
parallel for investigating the role of DNA methylation
in cross-tissue studies of complex disease.
Conclusions
This study demonstrates the utility of combining oxBS-
treatment with the Illumina 450k methylation array to
systematically quantify 5hmC across the genome. Our
study highlights region-specific patterns of 5hmC in the
human brain, with overall higher levels observed in the
cerebellum than the prefrontal cortex, and notable
differences in the genomic location of the most hydroxy-
methylated loci between these brain regions. Loci dem-
onstrating the greatest differences between brain regions
(TS-HMPs) are highly enriched at CpG islands and in
the gene body. We also identify considerable inter-
individual variation in 5hmC at a subset of loci within
each brain region, with these variable regions being par-
ticularly enriched in CpG islands and depleted in inter-
genic regions and the proximal promoter. Finally, we
were able to confirm our findings in a second independ-
ent set of matched prefrontal cortex and cerebellum
samples. Given the enrichment of 5hmC in the vicinity
of genes involved in nervous system development and
Table 2 The most hydroxymethylated loci in prefrontal cortex and cerebellum are enriched in distinict genomic regions
Loci with detectable 5hmC in brain (%) 1,000 loci with highest 5hmC in prefrontal cortex 1,000 loci with highest 5hmC in cerebellum
Detectable 5hmC
sites (%)
Enrichment
(95 % CI)
P value Detectable 5hmC
sites (%)
Enrichment
(95 % CI)
P value
All probes (N = 79,263) 1,000 - - 1,000 - -
CpG island feature
Island 7,837 (9.9 %) 121 (12.1 %) 1.25 (1.03–1.52) 0.022 275 (27.5 %) 3.46 (2.99–3.99) 7.01E-55
Shore 22,593 (28.5 %) 472 (47.2 %) 2.24 (1.97–2.55) 3.19E-35 276 (27.6 %) 0.96 (0.83–1.10) 0.549
Shelf 11,674 (14.7 %) 93 (9.3 %) 0.59 (0.47–0.74) 4.29E-07 121 (12.1 %) 0.80 (0.65–0.97) 0.019
Outside 36,342 (45.8 %) 307 (30.7 %) 0.52 (0.46–0.60) 3.37E-22 326 (32.6 %) 0.57 (0.50–0.65) 2.94E-17
Unannotated 817 (1.0 %) 7 (0.7 %) 0.68 (0.27–1.41) 0.426 2 (0.2 %) 0.19 (0.02–0.70) 3.94E-03
Gene feature
Intergenic 9,604 (12.1 %) 89 (8.9 %) 0.71 (0.56–0.88) 1.48E-03 74 (7.4 %) 0.58 (0.45–0.74) 1.56E-06
Distal promoter 3,703 (4.7 %) 46 (4.6 %) 0.98 (0.71–1.33) 1.000 19 (1.9 %) 0.40 (0.24–0.62) 4.88E-06
Proximal promoter 16,979 (21.4 %) 365 (36.5 %) 2.11 (1.85–2.40) 3.10E-27 206 (20.6 %) 0.95 (0.81–1.11) 0.561
Gene body 46,238 (58.3 %) 474 (47.4 %) 0.64 (0.57–0.73) 5.30E-12 670 (67.0 %) 1.45 (1.27–1.66) 2.60E-08
Downstream 1,922 (2.4 %) 19 (1.9 %) 0.78 (0.47–1.23) 0.350 29 (2.9 %) 1.20 (0.80–1.74) 0.351
Unannotated 817 (1.0 %) 7 (0.7 %) 0.68 (0.27–1.41) 0.426 2 (0.2 %) 0.19 (0.02–0.70) 3.94E-03
Transcription factor binding Site 25,482 (32.1 %) 545 (54.5 %) 2.53 (2.22–2.87) 2.57E-47 383 (38.3 %) 1.31 (1.15–1.49) 4.97E-05
Dnase 1 hypersensitivity site 8,155 (10.3 %) 150 (15 %) 1.54 (1.28–1.84) 3.95E-06 143 (14.3 %) 1.45 (1.21–1.74) 8.42E-05
Alternative transcription events (N = 30,659 probes) 398 - - 451 - -
A3SS 798 (2.6 %) 8 (2.0 %) 0.77 (0.33–1.54) 0.632 22 (4.9 %) 1.92 (1.18–2.96) 6.74E-03
A5SS 827 (2.7 %) 12 (3.0 %) 1.12 (0.57–1.90) 0.640 17 (3.8 %) 1.41 (0.81–2.30) 0.185
AFE 9,159 (29.9 %) 158 (39.7 %) 1.55 (1.25–1.90) 3.41E-05 112 (24.8 %) 0.78 (0.62–0.96) 0.020
ALE 3,017 (9.8 %) 27 (6.8 %) 0.67 (0.43–0.99) 0.041 46 (10.2 %) 1.04 (0.75–1.42) 0.811
CE 16,604 (54.2 %) 185 (46.5 %) 0.74 (0.60–0.90) 2.37E-03 208 (46.1 %) 0.72 (0.60–0.88) 7.17E-04
CNE 3,755 (12.2 %) 53 (13.3 %) 1.10 (0.81–1.48) 0.490 62 (13.7 %) 1.14 (0.86–1.50) 0.347
EI 50 (0.2 %) 1 (0.3 %) 1.54 (0.04–9.04) 0.482 2 (0.4 %) 2.73 (0.32–10.43) 0.174
II 6,003 (19.6 %) 89 (22.4 %) 1.18 (0.92–1.50) 0.163 87 (12.3 %) 0.98 (0.77–1.25) 0.952
IR 3,529 (11.5 %) 63 (15.8 %) 1.45 (1.08–1.90) 0.011 80 (17.7 %) 1.66 (1.28–2.12) 1.08E-04
MXE 3,814 (12.4 %) 43 (10.8 %) 0.85 (0.61–1.17) 0.259 35 (7.8 %) 0.59 (0.41–0.84) 1.90E-03
The level of enrichment of the top 1,000 loci in each brain region was determined by Fisher’s exact test. 5hmC, 5-hydroxymethylcytosine; CI, confidence interval;
A3SS, alternative 3’ splice site; A5SS, alternative 5’ splice site; AFE, alternative first exon; ALE, alternative last exon; CE, cassette exon; CNE, constitutive exon; EI, exon
isoforms; II, intron isoforms; IR, intron retention; MXE, mutually exclusive exon
Lunnon et al. Genome Biology  (2016) 17:27 Page 9 of 14
function, and the inability to distinguish this modifi-
cation from 5mC using standard BS-based methods,
we propose that approaches described here can be
used to interrogate the role of 5hmC in neurological/
neuropsychiatric phenotypes and disease.
Methods
Sample preparation
Our discovery cohort comprised prefrontal cortex and
cerebellum samples dissected from eight individuals.
First, brain tissue from six control donors, with no
evidence of neurological impairment, was obtained
from the London Neurodegenerative Disease Brain
Bank (LNDBB) (http://www.kcl.ac.uk/ioppn/depts/bcn/
Our-research/Neurodegeneration/brain-bank.aspx). For
each sample, genomic DNA was extracted from
100 mg of tissue using a standard phenol-chloroform
extraction method. Additionally, two control cerebel-
lum samples, provided by CEGX, were run alongside.
Sample characteristics for all discovery samples are
detailed in Additional file 2: Table S12. Validation
data were generated from matched prefrontal cortex
and cerebellum samples from 18 control donors, with
no evidence of neurological impairment, currently be-
ing profiled as part of an independent study in our
lab.
Table 3 The 1,000 top tissue-specific hydroxymethylated positions (TS-HMPs) between the prefrontal cortex and cerebellum are
enriched in distinct genomic regions
Loci with detectable
5hmC in brain (%)
Top 1,000 loci with tissue-specific differences
Sites with detectable
5hmC (%)
Enrichment
(95 % CI)
P value
All probes (N = 79,263) 1,000 - -
CpG island feature
Island 7,837 (9.9 %) 317 (31.7 %) 4.23 (3.68–4.85) 6.37E-79
Shore 22,593 (28.5 %) 209 (20.9 %) 0.66 (0.57–0.77) 6.20E-08
Shelf 11,674 (14.7 %) 92 (9.2 %) 0.59 (0.47–0.73) 2.64E-07
Outside 36,342 (45.8 %) 381 (38.1 %) 0.73 (0.64–0.83) 9.82E-07
Unannotated 817 (1.0 %) 1 (0.1 %) 0.10 (0.00–0.54) 7.00E-04
Gene feature
Intergenic 9,604 (12.1 %) 132 (13.2 %) 1.10 (0.91–1.33) 0.306
Distal promoter 3,703 (4.7 %) 25 (2.5 %) 0.52 (0.34–0.78) 6.30E-04
Proximal promoter 16,979 (21.4 %) 121 (12.1 %) 0.50 (0.41–0.61) 3.32E-14
Gene body 46,238 (58.3 %) 690 (69.0 %) 1.59 (1.39–1.82) 5.15E-12
Downstream 1,922 (2.4 %) 31 (3.1 %) 1.29 (0.87–1.85) 0.178
Unannotated 817 (1.0 %) 1 (0.1 %) 0.10 (0.00–0.54) 7.00E-04
Transcription factor binding site 25,482 (32.1 %) 125 (12.5 %) 0.30 (0.25–0.36) 1.30E-46
Dnase 1 hypersensitivity site 8,155 (10.3 %) 280 (28.0 %) 3.39 (2.94–3.91) 3.51E-54
Alternative transcription events (N = 30,659) 404 - -
A3SS 798 (2.6 %) 14 (3.5 %) 1.34 (0.72–2.29) 0.270
A5SS 827 (2.7 %) 17 (4.2 %) 1.58 (0.91–2.59) 0.087
AFE 9,159 (29.9 %) 92 (22.8 %) 0.69 (0.54–0.88) 1.77E-03
ALE 3,017 (9.8 %) 40 (9.9 %) 1.01 (0.71–1.40) 0.933
CE 16,604 (54.2 %) 202 (50.0 %) 0.85 (0.69–1.04) 0.097
CNE 3,755 (12.2 %) 69 (17.1 %) 1.48 (1.12–1.92) 4.70E-03
EI 50 (0.2 %) 1 (0.2 %) 1.52 (0.04–8.91) 0.487
II 6,003 (19.6 %) 59 (14.6 %) 0.70 (0.52–0.93) 0.011
IR 3,529 (11.5 %) 54 (13.4 %) 1.19 (0.87–1.59) 0.240
MXE 3,814 (12.4 %) 39 (9.7 %) 0.75 (0.53–1.05) 0.095
The level of enrichment of the top 1,000 loci was determined by Fisher’s exact test. 5hmC, 5-hydroxymethylcytosine; CI, confidence interval; A3SS, alternative 3’
splice site; A5SS, alternative 5’ splice site; AFE, alternative first exon; ALE, alternative last exon; CE, cassette exon; CNE, constitutive exon; EI, exon isoforms; II, intron
isoforms; IR, intron retention; MXE, mutually exclusive exon
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Table 4 The most variable hydroxymethylated loci in prefrontal cortex and cerebellum are enriched in distinct genomic regions
Loci with detectable
5hmC in brain (%)
Top 1,000 most variable loci in prefrontal cortex Top 1,000 most variable loci in cerebellum
Sites with detectable
5hmC (%)
Enrichment
(95 % CI)
P value Sites with detectable
5hmC (%)
Enrichment
(95 % CI)
P value
All probes (N = 79,263) 1,000 - - 1,000 - -
CpG island feature
Island 7,837 (9.9 %) 159 (15.9 %) 1.72 (1.44–2.05) 4.037E-09 301 (30.1 %) 3.92 (3.41–4.51) 2.41E-69
Shore 22,593 (28.5 %) 270 (27.0 %) 0.93 (0.80–1.07) 0.307 171 (17.1 %) 0.52 (0.44–0.61) 9.25E-17
Shelf 11,674 (14.7 %) 107 (10.7 %) 0.69 (0.56–0.85) 2.23E-04 134 (13.4 %) 0.90 (0.74–1.08) 0.261
Outside 36,342 (45.8 %) 376 (37.6 %) 0.71 (0.62–0.81) 1.82E-07 281 (28.1 %) 0.46 (0.40–0.53) 3.04E-30
Unannotated 817 (1.0 %) 88 (8.8 %) 9.26 (7.28–11.67) 4.97E-50 113 (11.3 %) 12.23 (9.85–15.09) 1.10E-74
Gene feature
Intergenic 9,604 (12.1 %) 99 (9.9 %) 0.80 (0.64–0.98) 0.032 80 (8.0 %) 0.63 (0.49–0.79) 3.86E-05
Distal promoter 3,703 (4.7 %) 36 (3.6 %) 0.76 (0.53–1.06) 0.113 30 (3.0 %) 0.63 (0.42–0.91) 0.010
Proximal promoter 16,979 (21.4 %) 172 (17.2 %) 0.76 (0.64–0.90) 1.10E-03 113 (11.3 %) 0.47 (0.38–0.57) 1.03E-16
Gene body 46,238 (58.3 %) 583 (58.3 %) 1.00 (0.88–1.14) 1.000 642 (64.2 %) 1.28 (1.12–1.46) 1.78E-04
Downstream 1,922 (2.4 %) 22 (2.2 %) 0.91 (0.56–1.38) 0.756 22 (22.0 %) 0.91 (0.56–1.38) 0.756
Unannotated 817 (1.0 %) 88 (8.8 %) 9.26 (7.28–11.67) 4.97E-50 113 (11.3 %) 12.23 (9.85–15.09) 1.10E-74
Transcription factor binding site 25,482 (32.1 %) 298 (29.8 %) 0.90 (0.78–1.03) 0.117 242 (24.2 %) 0.67 (0.58–0.78) 4.57E-08
Dnase 1 hypersensitivity site 8,155 (10.3 %) 77 (7.7 %) 0.73 (0.57–0.92) 6.33E-03 61 (6.1 %) 0.57 (0.43–0.74) 4.56E-06
Alternative transcription events (N = 30,659) 385 - - 418 - -
A3SS 798 (2.6 %) 15 (3.9 %) 1.52 (0.84–2.55) 0.144 15 (3.6 %) 1.39 (0.77–2.34) 0.214
A5SS 827 (2.7 %) 10 (2.6 %) 0.96 (0.46–1.80) 1.000 17 (4.1 %) 1.53 (0.88–2.49) 0.094
AFE 9,159 (29.9 %) 103 (26.8 %) 0.86 (0.68–1.08) 0.197 82 (19.6 %) 0.57 (0.44–0.73) 2.55E-06
ALE 3,017 (9.8 %) 36 (9.4 %) 0.95 (0.65–1.34) 0.863 38 (9.1 %) 0.92 (0.64–1.28) 0.679
CE 16,604 (54.2 %) 200 (51.9 %) 0.92 (0.74–1.13) 0.410 187 (44.7 %) 0.69 (0.56–0.84) 1.38E-04
CNE 3,755 (12.2 %) 60 (15.6 %) 1.32 (0.98–1.75) 0.051 86 (20.6 %) 1.86 (1.44–2.37) 1.95E-06
EI 50 (0.2 %) 1 (0.3 %) 1.59 (0.04–9.35) 0.471 2 (0.5 %) 2.94 (0.35–11.27 0.155
II 6,003 (19.6 %) 74 (19.2 %) 0.98 (0.75–1.27) 0.897 69 (16.5 %) 0.81 (0.62–1.06) 0.121
IR 3,529 (11.5 %) 41 (10.6 %) 0.92 (0.64–1.27) 0.688 68 (16.3 %) 1.49 (1.13–1.95) 4.24E-03
MXE 3,814 (12.4 %) 40 (10.4 %) 0.82 (0.57–1.14) 0.244 31 (7.4 %) 0.56 (0.38–0.82) 1.26E-03
The level of enrichment of the top 1,000 loci in each brain region was determined by Fisher’s exact test. 5hmC, 5-hydroxymethylcytosine; CI, confidence interval; A3SS, alternative 3’ splice site; A5SS, alternative 5’ splice
site; AFE, alternative first exon; ALE, alternative last exon; CE, cassette exon; CNE, constitutive exon; EI, exon isoforms; II, intron isoforms; IR, intron retention; MXE, mutually exclusive exon
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Bisulfite (BS) and oxidative-bisulfite (oxBS) treatment
For each sample DNA was treated using: (1) the Zymo
BS conversion kit; (2) the Cambridge Epigenetix BS
conversion module; and (3) the Cambridge Epigenetix
oxBS conversion module. For Zymo BS, 500 ng DNA
from each sample was sodium BS-treated using the
Zymo EZ 96 DNA methylation kit (Zymo Research) ac-
cording to the manufacturer’s standard protocol. For
CEGX BS and CEGX oxBS samples, 4 μg of high mo-
lecular weight genomic DNA was sheared into <10 kb
fragments using a Covaris g-Tube. The fragmented DNA
was subsequently concentrated into a total volume of
40 μL by passing the sample through a geneJET purifica-
tion column. The 40 μL was split into two 20 μL sam-
ples and processed using the TrueMethyl kit following
the manufacturer’s instructions. We performed enzyme
digestion of the CEGX conversion controls as recom-
mended by the manufacturer, and all samples showed
satisfactory conversion (see Additional file 1: Figure S6
for example output).
Illumina Infinium BeadArray
DNA modifications were quantified using the Illumina
Infinium Human 450K Methylation Array according to
the manufacturer’s instructions, with minor amend-
ments. In brief, the DNA input to the MSA4 plate for
whole genome amplification was increased from 4 μL to
7 μL of CEGX BS/oxBS treated DNA. To compensate
for the increased DNA volume, the concentration of
NaOH was increased to 0.4 M and only 1 μL added to
the MSA4 plate.
Quality control (QC) and data normalization
All computations and statistical analyses were performed
within the R statistical environment (version 3.1.2) [27]
and Bioconductor [28]. Signal intensities were imported
into R using the methylumi package [29]. Initial QC
checks were performed to assess concordance between
reported and predicted gender. Non-CpG SNP probes
on the array were used to confirm that samples where
sourced from the same individual were genetically
identical (Additional file 1: Figure S7). Data were pre-
processed using wateRmelon (version 1.4.0) [30], with a
custom P filter threshold of 5 % of sites with a detection
P value <0.05. No precedents have yet been set for pre-
processing and normalizing oxBS data. We therefore
tested all of the different normalization strategies avail-
able within the wateRmelon package. We found that
although other normalization strategies scored highly
within each metric, data analyzed using dasen consist-
ently scored well for each metric (Additional file 2:
Table S13), and were therefore used for data normalization.
Non-CpG SNP probes, probes that have been reported to
contain common (MAF >5 %) SNPs in the CG or single
Fig. 5 Canonical differences in DNA methylation in standard BS-treated DNA can be masked by 5hmC differences. There was no difference in
levels of DNA modifications (5mC + 5hmC) in BS-treated DNA between the prefrontal cortex and the cerebellum. However, when examining true
5mC levels (oxBS) there are higher levels of DNA methylation at the 3’ end of the gene body in the prefrontal cortex than the cerebellum. Key:
BS-treated (5mC + 5hmC levels) prefrontal cortex DNA (red), BS-treated (5mC + 5hmC levels) cerebellum DNA (green), oxBS-treated (5mC levels
only) prefrontal cortex DNA (blue), oxBS-treated (5mC level only) prefrontal cortex DNA (pink)
Lunnon et al. Genome Biology  (2016) 17:27 Page 12 of 14
base extension position, or probes that were non-specific or
mismapped [31, 32], were flagged and disregarded in the
evaluation of our results, leaving 374,094 probes for
analysis.
Data analysis
The level of 5-hmC within each sample was identified by
subtracting the oxBS (CEGX) beta-value from the BS
(CEGX) beta value at each probe on the 450K array
(ΔβBS-oxBS) in each sample. A threshold for detection of
5hmC was established by determining the lowest fifth
percentile in the data (that is, -0.09158275 in this study).
We then applied this value as a threshold for the positive
data. Sites with an average 5hmC level in either the pre-
frontal cortex or cerebellum above this level (that is,
+0.09158275) were classified as having ‘detectable’ levels
of 5hmC. Illumina 450K array probes were annotated
using ENCODE annotation [25], and Fisher’s exact test
was used to determine if 5hmC was enriched in specific
genomic regions. Normalized 5hmC levels are available on
our online analytical database HABIT for the 79,263 sites
we identified as having ‘detectable’ 5hmC in one or both
brain regions (http://epigenetics.iop.kcl.ac.uk/HMC/).
Pathway analyses
Illumina UCSC gene annotation was used to create a
test gene list from the hydroxymethylated probes in
the prefrontal cortex (N = 37,145) and the cerebellum
(N = 65,563), or the TS-HMPs (N = 1,000). A logistic
regression approach was used to test if gene lists pre-
dicted pathway membership while controlling for the
number of probes annotated to each gene. Pathways
were downloaded from the Gene Ontology website
(http://geneontology.org/) and all genes annotated to
parent terms were also included. All genes with at least
one Illumina probe annotated and annotated to at least
one GO pathway were considered. Pathways were filtered
to those with between 10 and 2,000 genes in them. After
applying this method to all pathways, significant pathways
(P <0.05) were taken and grouped where overlapping
genes explained the signal. This was achieved by taking
the most significant pathway, and retesting all remaining
significant pathways while controlling additionally for the
best term. If the test genes no longer predicted the path-
way, the term was said to be explained by the most signifi-
cant pathway, and hence these pathways were grouped
together. This algorithm was repeated, taking the next
most significant term, until all pathways were considered
as the most significant or found to be explained by a more
significant term.
Determining 5mC and 5hmC in a canonical gene
A sliding window approach was used to calculate
average 5mC and 5hmC levels in a gene. To investigate
canonical differences in 5hmC we calculated the moving
average for 5mC (oxBS) and 5hmC (ΔβBS-oxBS) in the
79,263 loci deemed to be hydroxymethylated for over-
lapping 1 % sliding windows from 5 kb upstream of the
gene to 5 kb downstream of the gene. To investigate
canonical differences in data derived from BS-treated
DNA, which may be driven by 5hmC differences we
calculated the moving average for BS-treated DNA
(5mC + 5hmC) and for oxBS DNA (5mC) in the
374,094 loci that passed QC for overlapping 1 % slid-
ing windows from 5 kb upstream of the gene to 5 kb
downstream of the gene.
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